<DOC>
	<DOCNO>NCT01522989</DOCNO>
	<brief_summary>This study patient advance solid tumor malignancy ( cancer spread part body ) . The purpose study test safety effectiveness new combination drug , PD-0332991 5-Fluorouracil Oxaliplatin patient advance solid tumor malignancy . PD-0332991 stop cell divide block enzyme call cyclin-dependent kinase ( CDK ) , cancer cell need grow divide . By inhibit enzyme , PD-0332991 prevent cancer cell grow dividing , 5-Fluorouracil Oxaliplatin damage cell , hopefully increase kill cancer cell , thus decrease tumor body . PD-0332991 investigational experimental anti-cancer agent yet approve Food Drug Administration use colorectal cancer . It give pill take day one week follow one week . 5-Fluorouracil Oxaliplatin administer infusion vein every 2 week approve used chemotherapy several cancer .</brief_summary>
	<brief_title>PD-0332991 , 5-FU , Oxaliplatin Advanced Solid Tumor Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Retinoblastomapositive , histologically proven advanced solid tumor malignancy curative therapy exist Biopsy accessible tumor deposit Corrected QT interval le 500 millisecond EKG ECOG preformance status 02 Subjects brain metastasis history previously treat brain metastasis treat surgery stereotactic radiosurgery least 4 week prior enrollment baseline MRI show evidence active intracranial disease treatment steroid within 1 week study enrollment . Adequate hepatic , bone marrow , renal function Partial thromboplastin time must &lt; /= 1.5 x upper limit normal range INR &lt; 1.5 . Subjects anticoagulant permit enroll long INR acceptable therapeutic range . Life expectancy &gt; 12 week Women childbearing potential must negative serum pregnancy test within 14 day prior initiation treatment and/or postmenopausal woman must amenorrheic least 12 month . Subject capable understanding comply parameter protocol able sign date inform consent . Intolerant , ineligible 5FU , oxaliplatin and/or combination CNS metastases meet criterion outline inclusion criterion Peripheral neuropathy &gt; /= Grade 2 baseline peripheral neuropathy &gt; /= Grade 1 neuropathic pain Active severe infection know chronic infection HIV hepatitis B virus Cardiovascular disease problem include unstable angina , therapy lifethreatening ventricular arrhythmia myocardial infarction , stroke , congestive heart failure within last 6 month . Lifethreatening visceral disease severe concurrent disease Women pregnant breastfeeding Anticipated patient survival 3 month Concurrent use know CYP 3A4 inhibit activate medication Clinically significant uncontrolled major medical condition ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced</keyword>
	<keyword>Refractory</keyword>
</DOC>